This study was published 10 March 2025.
High-dose vitamin D reduced disease activity in clinically isolated syndrome (CIS) and in early relapsing-remitting multiple sclerosis (MS), the D-Lay MS clinical trial showed.
Key Takeaways
High-dose vitamin D reduced disease activity in early MS and CIS compared with placebo.
Patients taking vitamin D had a longer time to disease activity: 432 days versus 224 days.
No severe adverse events were related to high-dose vitamin D.